


Comparative analysis of RNA-Seq data with DESeq2

Simon Anders
EMBL Heidelberg



Two applications of RNA-Seq

Discovery

- find new transcripts
- find transcript boundaries
- find splice junctions

Comparison

Given samples from different experimental conditions, find effects of the treatment on

- gene expression strengths
- isoform abundance ratios, splice patterns, transcript boundaries

Sequencing count data

	control-1	control-2	control-3	treated-1	treated-2
FBgn0000008	78	46	43	47	89
FBgn0000014	2	0	0	0	0
FBgn0000015	1	0	1	0	1
FBgn0000017	3187	1672	1859	2445	4615
FBgn0000018	369	150	176	288	383
[...]					

- RNA-Seq
- Tag-Seq
- ChIP-Seq
- HiC
- Bar-Seq
- ...

Counting rules

- Count reads, not base-pairs
- Count each read at most once.
- Discard a read if
 - it cannot be uniquely mapped
 - its alignment overlaps with several genes
 - the alignment quality score is bad
 - (for paired-end reads) the mates do not map to the same gene

Why we discard non-unique alignments

gene A




control condition




gene B



treatment condition






Normalization for library size


- If sample A has been sampled deeper than sample B, we expect counts to be higher.
- Naive approach: Divide by the total number of reads per sample
- Problem: Genes that are strongly and differentially expressed may distort the ratio of total reads.

Normalization for library size



Normalization for library size

Histogram of $\log_2(\text{sample2}/\text{sample1})$



Normalization for library size

To compare more than two samples:

- Form a “virtual reference sample” by taking, for each gene, the geometric mean of counts over all samples
- Normalize each sample to this reference, to get one scaling factor (“size factor”) per sample.


Anders and Huber, 2010
similar approach: Robinson and Oshlack, 2010

Counting noise


In RNA-Seq, noise (and hence power) depends on count level.

Why?


The Poisson distribution




- This bag contains very many small balls, 10% of which are red.
- Several experimenters are tasked with determining the percentage of red balls.
- Each of them is permitted to draw 20 balls out of the bag, without looking.




$$3 / 20 = 15\%$$




$$1 / 20 = 5\%$$




$$2 / 20 = 10\%$$




$$0 / 20 = 0\%$$



$$7 / 100 = 7\%$$



$$10 / 100 = 10\%$$



$$8 / 100 = 8\%$$




$$11 / 100 = 11\%$$

Poisson distribution: Counting uncertainty

expected number of red balls	standard deviation of number of red balls	relative error in estimate for the fraction of red balls
10	$\sqrt{10} = 3$	$1 / \sqrt{10} = 31.6\%$
100	$\sqrt{100} = 10$	$1 / \sqrt{100} = 10.0\%$
1,000	$\sqrt{1,000} = 32$	$1 / \sqrt{1000} = 3.2\%$
10,000	$\sqrt{10,000} = 100$	$1 / \sqrt{10000} = 1.0\%$


The negative binomial distribution

A commonly used generalization of the Poisson distribution with *two* parameters




$$\Pr(Y = k) = \binom{k + r - 1}{r - 1} p^r (1 - p)^k \quad \text{for } k = 0, 1, 2, \dots$$


The NB from a hierarchical model



Biological sample with mean μ and variance v



Poisson distribution with mean q and variance q .



Negative binomial with mean μ and variance $q+v$.

Testing: Generalized linear models

Two sample groups, treatment and control.

Assumption:

- Count value for a gene in sample j is generated by NB distribution with mean $s_j \mu_j$ and dispersion α .

Null hypothesis:

- All samples have the same μ_j .

Alternative hypothesis:

- Mean is the same only within groups:

$$\log \mu_j = \beta_0 + x_j \beta_T$$

$x_j = 0$ for if j is control sample

$x_j = 1$ for if j is treatment sample

Testing: Generalized linear models

$$\log \mu_j = \beta_0 + x_j \beta_T$$

$x_j = 0$ for if j is control sample

$x_j = 1$ for if j is treatment sample

Calculate the coefficients β that fit best the observed data.

Is the value for β_T significantly different from null?

Can we reject the null hypothesis that it is merely cause by noise?

The Wald test gives us a p value.

p values

The p value from the Wald test indicates the probability that the observed difference between treatment and control (as indicated by β_T), or an even stronger one, is observed even though there is no true treatment effect.

Multiple testing

- Consider: A genome with 10,000 genes
- We compare treatment and control. Unbeknownst to us, the treatment had no effect at all.
- How many genes will have $p < 0.05$?

Multiple testing

- Consider: A genome with 10,000 genes
- We compare treatment and control. Unbeknownst to us, the treatment had no effect at all.
- How many genes will have $p < 0.05$?
- $0.05 \times 10,000 = 500$ genes.

Multiple testing

- Consider: A genome with 10,000 genes
- We compare treatment and control
- Now, the treatment is real.

- 1,500 genes have $p < 0.05$.
- How many of these are false positives?

Multiple testing

- Consider: A genome with 10,000 genes
- We compare treatment and control
- Now, the treatment is real.

- 1,500 genes have $p < 0.05$.
- How many of these are false positives?

- 500 genes, i.e., 33%

Dispersion

- A crucial input to the GLM procedure and the Wald test is the estimated strength of within-group variability.
- Getting this right is the hard part.

Replication at what level?

- Prepare several libraries from the same sample (**technical replicates**).
 - controls for measurement accuracy
 - allows conclusions about just this sample

Replication at what level?

- Prepare several samples from the same cell-line (**biological replicates**).
 - controls for measurement accuracy *and* variations in environment an the cells' response to them.
 - allows for conclusions about the specific cell line

Replication at what level?

- Derive samples from different individuals (**independent samples**).
 - controls for measurement accuracy, variations in environment *and* variations in genotype.
 - allows for conclusions about the species

How much replication?

Two replicates permit to

- globally estimate variation

Sufficiently many replicates permit to

- estimate variation for each gene
- randomize out unknown covariates
- spot outliers
- improve precision of expression and fold-change estimates

Estimation of variability is the bottleneck

Example: A gene differs by 20% between samples within a group ($CV=0.2$)

What fold change gives rise to $p=0.0001$?

Number of samples	4	6	8	10	20	100
CV known	55%	45%	39%	35%	35%	11%
CV estimated						

(assuming normality and use of z or t test, resp.)

Estimation of variability is the bottleneck


Example: A gene differs by 20% between samples within a group ($CV=0.2$)

What fold change gives rise to $p=0.0001$?

Number of samples	4	6	8	10	20	100
CV known	55%	45%	39%	35%	35%	11%
CV estimated	1400% (14x)	180% (1.8x)	91%	64%	31%	11%

(assuming normality and use of z or t test, resp.)

Shrinkage estimation of variability



Comparison of normalized counts
between two replicate samples

(Drosophila cell culture, treated with siRNA,
data by Brooks et al., 2011)

Core assumption:

Genes of similar expression strength
have similar sample-to-sample
variance.

Under this assumption, we can
estimate variance with more
precision.


Baldi & Long (2001); Lönnsted & Speed
(2002); Smyth (2004); Robinson,
McCarthy & Smyth (2010); Wu et al
(2013);...

Fisher's exact test between two samples

Example data: fly cell culture, knock-down of pasilla

(Brooks et al., Genome Res., 2011)

knock-down sample T2
versus
control sample U3



red: significant genes according to Fisher test (at 10% FDR)



Fisher's exact test between two samples

Example data: fly cell culture, knock-down of pasilla

(Brooks et al., Genome Res., 2011)

knock-down sample T2
versus
control sample U3

control sample U2
versus
control sample U3



red: significant genes according to Fisher test (at 10% FDR)

Tasks in comparative RNA-Seq analysis

- Estimate fold-change between control and treatment
- Estimate variability within groups
- Determine significance



the hard part

Estimation of variability

Estimation of variability is the bottleneck

Example: A gene typically differs by 20% between replicate samples ($CV=0.2$)

What fold change gives rise to $p=0.0001$?

Number of samples	2x2	2x3	2x4	2x5	2x10	2x50
CV known	55%	45%	39%	35%	35%	11%
CV estimated						

(assuming normality and use of z or t test, resp.)

Estimation of variability is the bottleneck


Example: A gene differs by 20% between samples within a group (CV=0.2)

What fold change gives rise to $p=0.0001$?

Number of samples	2x2	2x3	2x4	2x5	2x10	2x50
CV known	55%	45%	39%	35%	35%	11%
CV estimated	1400% (14x)	180% (1.8x)	91%	64%	31%	11%

(assuming normality and use of z or t test, resp.)

Shrinkage estimation of variability



For each gene, estimate within-group variance/dispersion with Cox-Reid maximum-likelihood

[McCarthy et al., NAR, 2012]

Dispersion

- Minimum variance of count data:


$$v = \mu \quad (\text{Poisson})$$

- Actual variance:

$$v = \mu + \alpha \mu^2$$

- α : “dispersion” $\alpha = (\mu - v) / \mu^2$
(squared coefficient of variation of extra-Poisson variability)

Shrinkage estimation of variability




Core assumption:

Genes of similar expression strength have similar sample-to-sample variance.


Under this assumption, we can estimate variance with more precision.

Baldi & Long (2001); Lönnsted & Speed (2002); Smyth (2004); Robinson, McCarthy & Smyth (2010); Wu et al (2013);...

Shrinkage estimation of variability



Shrinkage estimation of variability



Empirical Bayes shrinkage

Model:

- Estimates scatter around fit due to
 - (i) uncertainty of dispersion estimation
 - (ii) true differences in dispersion
- Fitting a log-normal to the residuals provides estimates the sum of both.
- After subtracting expected width for (i), we are left with an empirical prior for (ii).

Dispersion shrinkage in DESeq2

- Estimate dispersion for each gene (using only that gene's count data)
- Fit dependence on mean.
- Fit log-normal empirical prior for true dispersion scatter around fitted values.
- Narrow prior to account for sampling width.
- Calculate maximum a-posteriori values as final dispersion estimates.
- Use raw values for high-dispersion outliers.


(Similar approach: DSS by Wu, Wang & Wu, 2013)

Testing



- DESeq2 fits a generalized linear model (GLM) of the negative binomial (NB) family.

Testing



- DESeq2 fits a generalized linear model (GLM) of the negative binomial (NB) family.
- Then, a Wald test is performed for the treatment coefficient



Outlier robustness



Cook's distance:
Change in fitted coefficients if the sample were removed



Testing and estimating

p values and effect sizes

or

What else to do with shrinkage?

All genes are differentially expressed
(but maybe only a very little bit)

No gene is perfectly decoupled from the other genes.

What do our p values really mean?


All genes are differentially expressed
(but maybe only a very little bit)

No gene is perfectly decoupled from the other genes.

What do our p values really mean?


Actually: “Have we got the sign right?”

Weak genes have exaggerated effect sizes




Shrinkage estimation of effect sizes

without shrinkage



with shrinkage



Shrinkage estimation of effect sizes

Procedure in DESeq2:

- Fit GLMs for all genes without shrinkage.
- Estimate normal empirical-Bayes prior from non-intercept coefficients.
- Adding log prior to the GLMs' log likelihoods results in a ridge penalty term.
- Fit GLMs again, now with the penalized likelihood to get shrunken coefficients.

From testing to estimating

- **Testing:** Is the gene's change noticeably different from zero?
Can we say whether it is up or down?
- **Estimation:** *How strong* is the change?

From testing to estimating

- **Testing:** Is the gene's change noticeably different from zero?
Can we say whether it is up or down?

- **Estimation:** *How strong is the change?*
How precise is this estimate?

→ Fold change estimates need information on their standard error.

From testing to estimating

→ Fold change estimates need information on their standard error.

It is convenient to have the same precision for all fold-change estimates.

Hence: Shrinkage. (variance-bias trade-off)

Gene ranking

How to rank a gene list to prioritize downstream experiments?

- by p value?
- by log fold change?

Gene ranking

How to rank a gene list to prioritize downstream experiments?

- by p value?
- by log fold change?
- by *shrunk* log fold change!

Gene-set enrichment analysis

Given the list of genes with strong effects in an experiment (“hits”): What do they mean?

Common approach: Take a collection of gene sets (e.g., GO, KEGG, Reactome, etc.), look for sets that are enriched in hits.

Gene-set enrichment analysis

Two approaches:

Categorical test: Is the gene set enriched for *significantly* differentially-expressed genes?

Continuous test: Are the fold changes of the genes in the set particularly strong?

Gene-set enrichment analysis: Worries

Power in RNA-Seq depends on counts.

Hit lists are enriched for genes with high count values: *strong* genes, and genes with *long* transcripts.

This causes bias in categorical tests.

(e.g., Oshlack & Wakefield, 2009)

Gene-set enrichment analysis: Worries

Fold-change estimates in RNA-Seq depends on counts.

Genes with low counts have exaggerated fold changes.

This causes bias in continuous tests.

(e.g., Oshlack & Wakefield, 2009)

Gene-set enrichment analysis: Shrinkage to the rescue

After shrinkage, log-fold-changes are homoskedastic. This makes a continuous test easy:


Gene-set enrichment analysis: Shrinkage to the rescue

After shrinkage, log-fold-changes (LFCs) are homoskedastic.

What about an ordinary t test:

- Is the mean of the LFCs of all the genes in the set non-zero?

GSEA with shrunken log fold changes



fly cell culture, knock-down of *pasilla* versus control (Brooks et al., 2011)

turquoise circles: genes in Reactome Path 3717570

“APC/C-mediated degradation of cell cycle proteins”

56 genes, avg LFC: -0.15, p value: $4 \cdot 10^{-11}$ (t test)

Critique

- The t test assumes the genes to be independent.
- However, genes in the same category tend to be correlated
- Our p values will be overly optimistic.
- We are working on it ...


More things to do with shrinkage: The rlog transformation

Many useful methods want homoscedastic data:

- Hierarchical clustering
- PCA and MDS


But: RNA-Seq data is not homoscedastic.

Visualization of rlog-transformed data: Sample clustering and PCA



Data: Parathyroid samples from Haglung et al., 2012

Visualization of rlog-transformed data: Gene clustering



More things to do with shrinkage:
The rlog transformation

RNA-Seq data is not homoscedastic.

- On the count scale, large counts have large (absolute) variance.
- After taking the logarithm, small counts show excessive variance.

More things to do with shrinkage:
The rlog transformation

Conceptual idea of the rlog transform:

Log-transform the average across samples of each gene's normalized count.

The “pull in” the log normalized counts towards the log averages. Pull more for weaker genes.

More things to do with shrinkage: The rlog transformation

Procedure:

- Fit log-link GLM with intercept for average and one coefficient per sample.
- Estimate empirical-Bayes prior from sample coefficients.
- Fit again, now with ridge penalty from EB prior.
- Return fitted linear predictors.

Summary: Effect-size shrinkage

A simple method that makes many things easier, including:

- visualizing and interpreting effect sizes
- ranking genes
- performing GSEA
- performing clustering and ordination analyses

Complex designs

Simple: Comparison between two groups.

More complex:

- paired samples
- testing for interaction effects
- accounting for nuisance covariates
- ...

GLMs: Blocking factor

Sample	treated	sex
S1	no	male
S2	no	male
S3	no	male
S4	no	female
S5	no	female
S6	yes	male
S7	yes	male
S8	yes	female
S9	yes	female
S10	yes	female

GLMs: Blocking factor

$$K_{ij} \sim NB(s_j \mu_{ij}, \alpha_{ij})$$

full model for gene i :

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T$$

reduced model for gene i :

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S$$

GLMs: Interaction

$$K_{ij} \sim NB(s_j \mu_{ij}, \alpha_{ij})$$

full model for gene i :

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T + \beta_i^I x_j^S x_j^T$$

reduced model for gene i :

$$\log \mu_{ij} = \beta_i^0 + \beta_i^S x_j^S + \beta_i^T x_j^T$$

GLMs: paired designs

- Often, samples are paired (e.g., a tumour and a healthy-tissue sample from the same patient)
- Then, using pair identity as blocking factor improves power.

full model:

$$\log \mu_{ijl} = \beta_i^0 + \begin{cases} 0 & \text{for } l = 1(\text{healthy}) \\ \beta_i^T & \text{for } l = 2(\text{tumour}) \end{cases}$$

reduced model:

$$\log \mu_{ij} = \beta_i^0$$

i gene
 j subject
 l tissue state

GLMs: Dual-assay designs

How does the affinity of an RNA-binding protein to mRNA change under some drug treatment?

Prepare control and treated samples (in replicates) and perform on each sample RNA-Seq and CLIP-Seq.

For each sample, we are interested in the ratio of CLIP-Seq to RNA-Seq reads.

How is this ratio affected by treatment?

GLMs: CLIP-Seq/RNA-Seq assay

full model:

$$\text{count} \sim \text{assayType} + \text{treatment} + \text{assayType:treatment}$$

reduced model:

$$\text{count} \sim \text{assayType} + \text{treatment}$$

GLMs: CLIP-Seq/RNA-Seq assay

full model:

$$\text{count} \sim \text{sample} + \text{assayType} + \text{assayType:treatment}$$

reduced model:

$$\text{count} \sim \text{sample} + \text{assayType}$$

Summary

- Estimating fold-changes without estimating variability is pointless.
- Estimating variability from few samples requires information sharing across genes (shrinkage)
- Shrinkage can also regularize fold-change estimates. (New in DESeq2)
- This helps with interpretation, visualization, clustering, ordination, etc.

Acknowledgements

Co-authors:

- Wolfgang Huber
- Alejandro Reyes
- Mike Love (MPI-MG Berlin)

Thanks also to

- the rest of the Huber group
- all users who provided feed-back

Funding:



EMBL



European Union:
FP7-health Project *Radiant*

